Future work should incorporate loss‐of‐function experiments, validation of results in diverse hepatoma cell lines, and in vivo models to confirm the universality and therapeutic potential of KDM6A modulation in the future. The gene discussed is KDM6A; the disease is hepatocellular carcinoma.